Xtant Medical Q2 revenue falls on asset sales and lost license revenue
XTNT•Outlook
- Xtant Medical lowers 2026 full-year revenue guidance to $99 mln-$103 mln from $101 mln-$105 mln
- Company cites ongoing headwinds in advanced wound care market impacting amnio product line
- Xtant Medical says cash and credit facility sufficient to fund operations for at least 12 months
Overview
- U.S. spinal and orthopedic device maker's Q2 revenue fell yr/yr, driven by asset sales and lost license revenue
- Q2 net loss widened, reflecting higher operating expenses including $5 mln exclusivity fee
- Company lowered full-year revenue guidance due to weaker biologics sales and amnio product headwinds
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Miss | $23 mln | $24.88 mln (2 Analysts) |
| Q2 Net Loss | Miss | $9.40 mln | $2.34 mln (2 Analysts) |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
Wall Street's median 12-month price target for Xtant Medical Holdings Inc is $1.35, about 202.7% above its August 10 closing price of $0.45.
